Affymetrix and Medical Prognosis Institute Collaborate to Develop Cancer Treatment Products
October 01 2008 - 8:00AM
Business Wire
Affymetrix Inc. (Nasdaq:AFFX) and Medical Prognosis Institute A/S
(MPI), a leading cancer diagnostic development company based in
Denmark, today announced that they have signed a Powered by
Affymetrix� (PbA) agreement. With this agreement, MPI gains
non-exclusive access to Affymetrix microarray technology to develop
and commercialize drug sensitivity prediction and prognostic
products for patients with cancer. Of 179 new anti-cancer drugs
tested in Phase I trials between 1976 and 1993, only 28 percent
were considered effective in Phase III.1 MPI believes the lack of
effect is highly correlated to the response rate, and is now
pursuing the opportunity to identify responders; for example, for
failed Phase III cancer drugs. Based on Affymetrix microarray
technology, MPI aims to market its own proprietary products
targeted at individual cancer prognosis and prediction of
anti-cancer treatment response. �Our partnership with Affymetrix
enables us to translate our discoveries into robust tools with
broad clinical utility to greatly improve the prognosis and
treatment of millions of people living with cancer. It also boosts
the probability of successful anti-cancer drug development in
partnership with drug companies,� said Jesper Drejet, president and
CEO of Medical Prognosis Institute. �We are confident of being able
to obtain regulatory clearance and achieve commercialization within
one to two years.� 2 �MPI�s cancer prognosis tools have the
potential to customize treatment schemes, revolutionize the control
of this disease and the chances of recovery,� said Kevin King,
president of Affymetrix. �Agreements such as this continue to
validate the need for microarrays for complex signatures for
reproducibility and accuracy. We are proud to help MPI advance its
ambitions to improve drug therapy choices and provide hope for
those struggling with this destructive disease.� Affymetrix offers
a continuous path to discover, develop and commercialize complex
biomarker signatures. The company partners with leading diagnostic
companies through its PbA program. The Affymetrix GeneChip� System
3000Dx is the only microarray instrumentation platform to receive
regulatory clearance by the U.S. FDA and is CE marked in the
European Union for in vitro diagnostic use. The CLIA-certified
Affymetrix Clinical Services Laboratory (ACSL) offers
microarray-based molecular diagnostic development support and
clinical trial testing services that enable customers to leverage
Affymetrix' technology and experience to bring more effective
molecular diagnostic tests to patients faster than ever before.
There are currently more than 20 different molecular assay tests
based on the Affymetrix platform under development by Affymetrix
and its PbA partners. 1 Sekine I., et al. Relationship between
objective responses in phase I trials and potential efficacy of
non-specific cytotoxic investigational new drugs. Annals of
Oncology 13:1300 (2002). 2 http://www.medical-prognosis.com/?id=6
About Medical Prognosis Institute Headquartered in H�rsholm,
Denmark, Medical Prognosis Institute�s (MPI) mission is to improve
cancer treatment with leading-edge technology based on DNA
microarrays. MPI uses proprietary individualized genomic profiling
of tumor tissue for prognostication of individual patients and for
determining which cancer patients will benefit from which specific
chemotherapy and/or radiation therapy. MPI is currently conducting
clinical trials to validate its claims that its products and
services will give cancer patients and oncologists necessary
insight to help make better treatment decisions. In addition, MPI,
also an Affymetrix Service Provider, recently began providing its
fast turn-around, high-quality DNA microarray services on a
fee-for-service basis to the academic and biopharmaceutical
industry in the discovery phase. For more information, visit
www.medical-prognosis.com, email info@medical-prognosis.com or call
+45 40862156. About Affymetrix Affymetrix GeneChip� microarray
technology is the industry-standard tool for analyzing complex
genetic information. After inventing microarray technology in the
late 1980s, Affymetrix scientists have been dedicated to developing
innovative products that provide researchers with a more complete
view of the genome. These products continue to accelerate genetic
research and enable scientists to develop diagnostics and tailor
treatments for individual patients by identifying and measuring the
genetic information associated with complex diseases. Today,
Affymetrix technology is used by the world�s top pharmaceutical,
diagnostic and biotechnology companies, as well as leading
academic, government and not-for-profit research institutes. More
than 1,700 systems have been shipped around the world and more than
13,000 peer-reviewed papers have been published using the
technology. Affymetrix is headquartered in Santa Clara, Calif., and
has manufacturing facilities in Sacramento, Calif., Cleveland,
Ohio, and Singapore. The company has about 1,100 employees
worldwide and maintains sales and distribution operations across
Europe and Asia. For more information about Affymetrix, please
visit the company�s website at www.affymetrix.com. Forward-looking
Statements All statements in this press release that are not
historical are �forward-looking statements� within the meaning of
Section 21E of the Securities Exchange Act as amended, including
statements regarding Affymetrix� �expectations,� �beliefs,�
�hopes,� �intentions,� �strategies� or the like. Such statements
are subject to risks and uncertainties that could cause actual
results to differ materially for Affymetrix from those projected,
including, but not limited to: risks and uncertainties relating to
commercial success of the agreement with Medical Prognosis
Institute discussed in this press release; risks of the company�s
ability to achieve and sustain higher levels of revenue, higher
gross margins and reduced operating expenses; uncertainties related
to technological approaches, manufacturing and product development;
personnel retention; uncertainties related to cost and pricing of
Affymetrix products; dependence on collaborative partners;
uncertainties related to sole-source suppliers; risks associated
with past and future acquisitions; uncertainties relating to FDA
and other regulatory approvals; competition; risks relating to
intellectual property of others and the uncertainties of patent
protection and litigation. These and other risk factors are
discussed in Affymetrix� Form 10-K for the year ended December 31,
2007, and other SEC reports, including its Quarterly Reports on
Form 10-Q for subsequent quarterly periods. Affymetrix expressly
disclaims any obligation or undertaking to release publicly any
updates or revisions to any forward-looking statements contained
herein to reflect any change in Affymetrix� expectations with
regard thereto or any change in events, conditions or circumstances
on which any such statements are based. NOTE: Affymetrix, the
Affymetrix logo and GeneChip� are registered trademarks owned or
used by Affymetrix Inc.
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jul 2023 to Jul 2024